trans-4-(Aminomethyl)cyclohexane carboxylic acid methylamide (t-AMCHA methylamide) inhibits the physical interaction between urokinase-type plasminogen activator and stratum corneum, and accelerates the recovery of barrier function

Katsuta, Yuji; Yoshida, Yuzo; Kawai, Eriko; Suetsugu, Masaru; Kohno, Y.; Inomata, Shinji; Kitamura, Kenji

doi:10.1016/j.jdermsci.2005.10.004

Cited by 12 publications

(16 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Katsuta et al . reported that TA could inhibit the physical interaction between urokinase‐type plasminogen activator and stratum corneum, which is the reason for the accelerating recovery of barrier function . However, there seems to be no direct evidence of TJ functioning as an intercellular permeability barrier under the TA repair experiments for both the SLS application and UVB irritation.…”

Section: Discussionmentioning

confidence: 99%

Tranexamic acid accelerates skin barrier recovery and upregulates occludin in damaged skin

et al. 2013

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Tranexamic acid accelerates skin barrier recovery and upregulates occludin in damaged skin

et al. 2013

View full text Add to dashboard Cite

show abstract

“…[16][17][18] Finally, further justification for the selection of tranexamic derivatives in this work comes from the fact that they have been used as antifibrinolytic drugs with no sign of cytotoxicity. [19][20][21] Herein, we report the design and the synthesis of a series of DOTA conjugates (4a-c) and their Gd-complexes of the type [Gd(L)(H 2 O)] 3 xH 2 O (5a-c, L = 4a-c) for use as a new class of bifunctional MRI CAs with liver-specific and blood-pool properties.…”

Section: Introductionmentioning

confidence: 99%

Gd-Complexes of 1,4,7,10-Tetraazacyclododecane-N,N′,N′′,N′′′-1,4,7,10-tetraacetic Acid (DOTA) Conjugates of Tranexamates as a New Class of Blood-Pool Magnetic Resonance Imaging Contrast Agents

Kim²,

Lee³

et al. 2010

J. Med. Chem.

View full text Add to dashboard Cite

Gd-complexes of the type [Gd(L)(H(2)O)]·xH(2)O (5a-c), where L is DOTA conjugates of tranexamic acid (4a) and tranexamic esters (4b,c), have been prepared as a new class of MRI blood-pool contrast agents (BPCAs). Thermodynamic stability (K(GdL)) and pharmacokinetic inertness of 5 compare well with or better than those of analogous MRI contrasting agents (CAs) such as Gd-DOTA and Gd-DTPA-BMA. Their R(1)-relaxivities are significantly higher than those of any of the clinically used MRI CAs. T(1)-weighted MR images of mice administered by 5c demonstrate high blood-pool effect with simultaneous contrast enhancement in liver. The structural uniqueness of 5c lies in the fact that it adopts macrocyclic DOTA instead of acyclic DTPA. In addition, 5c is nonionic and makes no resort to aromatic substituent(s) in the chelate backbone for the blood-pool enhancement. The nature of hepatobiliary uptake demonstrated by 5c may be explained in terms of lipophilicity of tranexamate in the chelate (4c). The cell cytotoxicity test shows no toxicity found with 5, suggesting their use as a practical MRI BPCAs.

show abstract

“…Based on previous studies showing that urokinase-type plasminogen activator is associated with barrier function in human skin 5 , 6 and that tranexamic acid, a plasminogen inhibitor, accelerates skin barrier recovery 2 , 7 , we initially expected that the impairment of human skin barrier function by Cry j1 would be due to plasminogen activation. Therefore, we examined the expression of plasminogen and plasmin by RT-PCR.…”

Section: Resultsmentioning

confidence: 99%

Tranexamic acid blocks the thrombin-mediated delay of epidermal permeability barrier recovery induced by the cedar pollen allergen, Cry j1

Nakanishi

Kumamoto

Denda

2018

Sci Rep

View full text Add to dashboard Cite

We previously demonstrated that Cry j1, the major pollen allergen of Cryptomeria japonica (Japanese cedar), transiently increases protease activity and intracellular Ca2+ concentration in cultured human keratinocytes, and delays recovery after stratum corneum barrier disruption in human skin ex vivo. Topical application of tranexamic acid or trypsin-type serine protease inhibitors accelerates barrier recovery. We hypothesized that tranexamic acid might prevent the transient protease activity increase and the barrier recovery delay induced by Cry j1. Here, we tested this hypothesis and examined the mechanism involved. In cultured human keratinocytes, knock-down of protease-activated receptor 1 (PAR-1) reduced the transient increase of calcium induced by Cry j1, whereas knock-down of PAR-2 did not. Knock-down of thrombin significantly reduced the transient increases of calcium concentration and protease activity. Tranexamic acid, soybean trypsin inhibitor, or bivalirudin (a thrombin inhibitor) also reduced the calcium elevation induced by Cry j1 and/or thrombin. Co-application of tranexamic acid or bivalirudin with Cry j1 to human skin ex vivo blocked the delay of barrier recovery. These results suggest that thrombin and PAR-1 or PAR-1-like receptor might mediate the adverse effects of Cry j1 on human epidermal keratinocytes, and could open up a new strategy for treating inflammatory skin diseases.

show abstract

trans-4-(Aminomethyl)cyclohexane carboxylic acid methylamide (t-AMCHA methylamide) inhibits the physical interaction between urokinase-type plasminogen activator and stratum corneum, and accelerates the recovery of barrier function

Cited by 12 publications

References 5 publications

Tranexamic acid accelerates skin barrier recovery and upregulates occludin in damaged skin

Tranexamic acid accelerates skin barrier recovery and upregulates occludin in damaged skin

Gd-Complexes of 1,4,7,10-Tetraazacyclododecane-N,N′,N′′,N′′′-1,4,7,10-tetraacetic Acid (DOTA) Conjugates of Tranexamates as a New Class of Blood-Pool Magnetic Resonance Imaging Contrast Agents

Tranexamic acid blocks the thrombin-mediated delay of epidermal permeability barrier recovery induced by the cedar pollen allergen, Cry j1

Contact Info

Product

Resources

About